Phreesia, Inc.
PHRUSPhreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
Enterprise value over trailing (LTM) vs. forward (NTM) fundamentals. Click an LTM cell to chart it.
- Sector
- Healthcare Services
- Sub-sector
- Healthcare IT & Revenue Cycle
- Listing
- PHR
- Country
- US
Annual financials & analyst forecasts
| $M | CY2021 | CY2022 | CY2023 | CY2024 | CY2025 | CY2026E | CY2027E |
|---|---|---|---|---|---|---|---|
| Revenue YoY | — | 32% | 27% | 18% | 14% | 6% | 5% |
| Revenue | $213M | $281M | $356M | $420M | $481M | $512M | $538M |
| Gross Profit | $132M | $172M | $232M | $285M | $326M | — | — |
| Gross Profit Margin | 61.8% | 61.1% | 65.2% | 67.9% | 67.9% | — | — |
| EBITDA | ($93M) | ($146M) | ($103M) | ($25M) | $29M | $249M | $261M |
| EBITDA Margin | -43.6% | -51.9% | -29.0% | -6.0% | 6.1% | 48.6% | 48.6% |
| EBIT | ($117M) | ($177M) | ($136M) | ($58M) | ($7M) | $234M | $246M |
| Net Income | ($118M) | ($176M) | ($137M) | ($59M) | $2M | $24M | $44M |
| Free Cash Flow | ($106M) | ($116M) | ($57M) | $8M | $64M | — | — |
| FCF Margin | -49.5% | -41.4% | -16.1% | 2.0% | 13.3% | — | — |
| Short-Term Debt | $0.22M | $0.25M | $1M | $1M | $3M | — | — |
| Long-Term Debt | $9M | $3M | $2M | $0.72M | $90M | — | — |
| Cash & Cash Equivalents | $314M | $177M | $88M | $84M | $74M | — | — |
| Net Debt | ($305M) | ($174M) | ($84M) | ($82M) | $19M | — | — |
| Net Debt / EBITDA | — | — | — | — | 0.6x | — | — |
| Rule of 40 | — | -9.7% | 10.8% | 19.8% | 27.8% | — | — |